Peptide inhibition of ccr3-mediated diseases or conditions
AssigneesThe Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsSteven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
Life of this patent
Estimating the term…
Abstract
A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
Claims16
A C—C chemokine receptor 3 (CCR3) peptide analog comprising the amino acid sequence Xaa1-Leu-Phe-Leu-Xaa2-Thr-Xaa3-Xaa4-Phe-Trp-Ile-His-Tyr (SEQ ID NO:15), wherein Xaa1 denotes Val or Leu, Xaa2 denotes Phe or Val, Xaa3 denotes Leu or Val, and Xaa4 denotes Pro or Val, and said peptide analog is PEGylated.
Dependencies are inferred from the claim text.